Jeffrey S. Humphrey

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene

Catherine A. Stolle, G.M. Glenn, Berton Zbar et al. · Human Mutation · 1998 · 476 citations

Life Sciences, Genetics, Molecular Genetics +16

Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia

Thomas O. Carpenter, Erik A. Imel, Mary D. Ruppe et al. · Journal of Clinical Investigation · 2014 · 317 citations

Medicine, Endocrinology, Pharmacokinetics +17

Localization of TGN38 to the trans-Golgi network: involvement of a cytoplasmic tyrosine-containing sequence.

Jeffrey S. Humphrey, Peter J. Peters, Lydia C. Yuan et al. · The Journal of Cell Biology · 1993 · 262 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Phase I Clinical Trial Design in Cancer Drug Development

Elizabeth A. Eisenhauer, Peter J. O’Dwyer, Michaele C. Christian et al. · Journal of Clinical Oncology · 2000 · 240 citations

Medicine, Oncology, Pharmacology +14